HPV Vaccine Not Linked To Autoimmune Disorders, Study

Featured Article
Academic Journal
Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Immune System / Vaccines;  Sexual Health / STDs;  Arthritis / Rheumatology
Article Date: 28 Jan 2012 – 16:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  

<!– rate icon rate article

Patient / Public:not yet rated

Healthcare Prof:not yet rated

A two-year study of nearly 190,000 girls and women, finds that Gardasil, the human papillomavirus (HPV) vaccine made by
Merck Co, does not trigger autoimmune disorders such as lupus, rheumatoid arthritis, type 1 diabetes and multiple
sclerosis. The results are published in the Journal of Internal Medicine.

Study lead author Dr Chun Chao, a research scientist at the Kaiser Permanente Department of Research Evaluation in
Pasadena, California, said in a statement released on Friday, that:

“This kind of safety information may help parents with vaccination decisions.”

“”These findings offer some assurance that among a large and generalizable female population, no safety signal for autoimmune
conditions was found following HPV4 vaccination in routine clinical use,” said Chao.

Gardasil is a “quadrivalent” vaccine because it helps protect against 4 types of HPV. In girls and young women age 9 to 26, it
targets 2 types that cause about 75% of cervical cancers, and 2 other types that cause 90% of cases of genital warts.

The vaccine, which is given as three injections over six months, also helps protect boys and men age 9 to 26 against 90% of
cases of genital warts.

Genital warts is the most common sexually transmitted infection in the US, where it infects about 6.2 million people every year.
It can also lead to cervical cancer in women.

Gardasil received US Food and Drug Administration (FDA) approval in 2006. But a longstanding concern about links with autoimmune disorders has surrounded the
vaccine, and many parents won’t let their children be vaccinated because of this.

However, Chao and fellow co-investigators from Kaiser Permanente told the press “most speculated associations have stemmed from
case reports that have not been confirmed by large, controlled epidemiologic studies”, and their investigation “presents findings
from a well-designed, post-licensure safety study of the vaccine on a large, ethnically diverse population”.

For the study, Chao and colleagues used electronic health records of 189,629 girls and women age 9 to 26 years in California.
The participants had been followed for six months after receiving each dose of the quadrivalent HPV vaccine in 2006-2008.

They found no increase in any of 16 autoimmune disorders in the vaccinated population compared to a matched population of
non-vaccinated girls and women. The 16 autoimmune disorders they looked for were:

“… immune thrombocytopenia, autoimmune hemolytic anemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile
rheumatoid arthritis, type 1 diabetes, Hashimoto’s disease, Graves’ disease, multiple sclerosis, acute disseminated
encephalomyelitis, other demyelinating diseases of the central nervous system, vaccine-associated demyelination, Guillain-Barré
syndrome, neuromyelitis optica, optic neuritis and uveitis.”

The researchers explained that the clinical trial data on the vaccine, and the subsequent adverse event reports, have important limitations
when it comes to assessing its safety profile.

This is because clinical trials are often based on a highly selected group of participants, the sample sizes are too small, and the
follow up is too short, to catch rare safety events such as autoimmune disorders.

And the adverse event reports are not easy to interpret because there is no comparison group, and it is hard to tell if the condition
developed before or after the vaccine.

So in their study, Chao and colleagues used methods like in-depth reviews of medical charts to ensure accuracy of diagnosis and
that the disease occurred after vaccination. Plus, disease incidence in the vaccinated group was contrasted with incidence in a
comparable unvaccinated group.

The results showed that:

  • Overall, there were 1,014 new-onset cases of an autoimmune disorder, of which 719 were eligible for case review, and 31
    (40%) were confirmed as new onset (ie emerged after vaccination).
  • Of these cases, “no cluster of disease onset in relation to vaccination timing, dose sequence or age was found for any
    autoimmune condition”.
  • None of the estimated incidence rate ratios was signficantly raised, except that for Hashimoto’s disease (IRR = 1.29, 95%
    confidence interval: 1.08-1.56).
  • “Further investigation of temporal relationship and biological plausibility revealed no consistent evidence for a safety signal
    for autoimmune thyroid conditions.”

The authors note that neither the investigators, nor an independent safety review committee, found any autoimmune safety
concerns in the study.

The study appears to have been well received by experts not connected to the investigation.

Dr. Harry Fischer, chief of the division of rheumatology at Beth Israel Medical Center in New York City welcomed the findings
and described the study as well-designed:

“This article speaks to the safety of the vaccine and helps to confirm that it does not contribute to the development of
autoimmune diseases,” he said, in a report from USA Today.

Merck Co funded the study.

Written by Catharine Paddock PhD

Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations

“Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine”;

C. Chao, N. P. Klein, C. M. Velicer, L. S. Sy, J. M. Slezak, H. Takhar, B. Ackerson, T. C. Cheetham, J. Hansen, K.

Deosaransingh, M. Emery, K.-L. Liaw and S. J. Jacobsen; Journal of Internal Medicine, Volume 271, Issue 2, February

2012, Pages: 193-203; Article first published online : 15 NOV 2011, DOI: 10.1111/j.1365-2796.2011.02467.x; Link to


Additional sources: Kaiser Permanente, USA Today report.

Please use one of the following formats to cite this article in your essay, paper or report:



Please note: If no author information is provided, the source is cited instead.

Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.

Everyday Health Network